- Home
- HOTH vs MBIO Comparison
HOTH vs MBIO Comparison
Compare HOTH & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOTH
- MBIO
- Stock Information
- Founded
- HOTH 2017
- MBIO 2015
- Country
- HOTH United States
- MBIO United States
- Employees
- HOTH N/A
- MBIO 80
- Industry
- HOTH Biotechnology: Pharmaceutical Preparations
- MBIO Biotechnology: Pharmaceutical Preparations
- Sector
- HOTH Health Care
- MBIO Health Care
- Exchange
- HOTH Nasdaq
- MBIO Nasdaq
- Market Cap
- HOTH 4.9M
- MBIO 7.3M
- IPO Year
- HOTH 2019
- MBIO N/A
- Fundamental
- Price
- HOTH $1.50
- MBIO $5.55
- Analyst Decision
- HOTH Strong Buy
- MBIO Strong Buy
- Analyst Count
- HOTH 4
- MBIO 1
- Target Price
- HOTH $4.75
- MBIO $2.00
- AVG Volume (30 Days)
- HOTH 25.5M
- MBIO 468.6K
- Earning Date
- HOTH 11-12-2024
- MBIO 03-10-2025
- Dividend Yield
- HOTH N/A
- MBIO N/A
- EPS Growth
- HOTH N/A
- MBIO N/A
- EPS
- HOTH N/A
- MBIO N/A
- Revenue
- HOTH N/A
- MBIO N/A
- Revenue This Year
- HOTH N/A
- MBIO N/A
- Revenue Next Year
- HOTH N/A
- MBIO N/A
- P/E Ratio
- HOTH N/A
- MBIO N/A
- Revenue Growth
- HOTH N/A
- MBIO N/A
- 52 Week Low
- HOTH $0.58
- MBIO $5.19
- 52 Week High
- HOTH $3.80
- MBIO $76.00
- Technical
- Relative Strength Index (RSI)
- HOTH 58.81
- MBIO 31.43
- Support Level
- HOTH $1.50
- MBIO $5.19
- Resistance Level
- HOTH $1.71
- MBIO $13.30
- Average True Range (ATR)
- HOTH 0.45
- MBIO 2.31
- MACD
- HOTH 0.04
- MBIO -0.47
- Stochastic Oscillator
- HOTH 25.54
- MBIO 2.14
About HOTH Hoth Therapeutics Inc.
Hoth Therapeutics Inc is a development-stage biopharmaceutical company. It is focused on targeted therapeutics for patients suffering from conditions such as atopic dermatitis, also known as eczema, chronic wounds, psoriasis, asthma, and acne. The company owns the BioLexa Platform which combines an FDA-approved zinc chelator with one or more approved antibiotics in a topical dosage form to address unchecked eczema flare-ups.
About MBIO Mustang Bio Inc.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.